Zheng Quan Ri Bao Wang·2025-11-13 13:44Core Insights - The company, Nuo Cheng Jian Hua, reported a strong revenue growth of 59.8% year-on-year for the first three quarters of 2025, reaching 1.12 billion yuan, primarily driven by the sales of its core product, the BTK inhibitor, Obinutuzumab [1] - The company expects to achieve breakeven for the full year of 2025, two years ahead of its profitability target, thanks to effective cost management and a significant licensing deal with Zenas [1] - The loss for the first three quarters of 2025 narrowed significantly by 74.8% to 70 million yuan, attributed to rapid revenue growth and improved cost efficiency [1] Group 1 - The licensing agreement with Zenas, valued at over 2 billion USD, is expected to enhance the company's financial performance and strategic value [1] - Zenas is advancing global Phase III clinical trials for Obinutuzumab in multiple sclerosis patients, which will further validate the drug's potential in autoimmune diseases [2] - The collaboration with Zenas alleviates future overseas development costs and allows the company to leverage Zenas's expertise in the autoimmune field [2] Group 2 - Nuo Cheng Jian Hua is strengthening its leadership in hematologic oncology with key therapies including Obinutuzumab, Tanibrutinib, and Mesutoclax [3] - The approval of Obinutuzumab for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma is expected to benefit more lymphoma patients [3] - The company aims to accelerate its globalization process and plans to push five to six innovative drugs for approval, with three to four products targeting global markets [3]